Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Clinical trial NCT03651128 · COMPLETED

Trial details

NCT number: NCT03651128
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2019-04-16
Primary completion: 2026-04-13
Enrollment: 386

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.